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Zika virus belongs to the family Flaviviridae as do 
other viruses like Dengue, West Nile and Yellow Fe-
ver. They are arboviruses transmitted by the Aedes 
species of mosquito. Zika virus was first isolated in 
rhesus monkeys in Uganda in 1947. Human infections 
of the virus were found between the 1960s and 1980s 
in Africa, the Americas, Asia and the Pacific. The sim-
ilarity in clinical presentation in Zika-infected patients 
compared with Dengue caused infections to be previ-
ously misdiagnosed as Dengue infection. The Zika 
virus pandemic in 2015 created a lot of concern global-
ly because of little information about available tech-
niques, samples as well as no available antiviral and 
vaccines for treatment and vaccination against infec-
tion. In addition, the vectors identified for transmis-
sion, Aedes aegypti and Aedes albopictus, were of 
great concern due to their ability to survive both tem-
perate and tropical climatic conditions, hence indicat-
ing the possible global spread of Zika virus infection. 
Almost two years after the report of infection in preg-
nant women in Brazil resulting in microcephalic ba-
bies, Zika virus was identified as a public health prob-
lem. Thus, a lot of research into early detection and 
prevention has been conducted to control the spread of 
the virus. This review paper highlights available infor-
mation on techniques currently available for diagnosis 
of infection caused by Zika virus. 
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Introduction 
 
Zika virus, a once neglected tropical microorganism, 
has been in existence since 1947 when it was first 
isolated from the blood of a sentinel rhesus monkey 
(Macacamulatta) in the Zika forest near Entebbe, 
Uganda (Dick et al. 1952). Human infections caused 
by this virus were found between the 1960s and 1980s 
in Africa, the Americas, Asia and the Pacific. The first 
major outbreak of Zika infection outside Africa was 
reported in the Yap Islands of Micronesia in 2007 
(Lanciotti et al. 2008). Fagbami in 1979 published a 
report of detection of Zika virus infection in 30% of 
the patient sera in four communities in Oyo state, 
Nigeria, along with three other Flavivirus, namely 
Yellow Fever (50%), West Nile (46%), and 
Wesselsbron (59%) (Fagbami 1979).  
In French Polynesia in 2013, a woman with 
Guillain-Barr syndrome who exhibited influenza-like 
symptoms was negative for all 4 serotypes of dengue 
by plaque reduction neutralization test but positive for 
Zika virus (Oehler et al. 2014). 
 In Yap state, patients were presenting dengue 
like symptoms with conjunctivitis. Thus, they were 
initially diagnosed serologically as being infected with 
dengue virus (Zika virus outbreak, 2007). However, 
molecular diagnoses by reverse transcription–PCR (RT
-PCR) and sequencing confirmed Zika virus infection, 
based on approximately 90% nucleotide identity with 
the Zika virus genome. 
In Brazil, the first confirmed case of Zika virus 
was reported in a patient who was initially exhibiting 
dengue-like symptoms (Zanluca et al. 2015). 
Serological and molecular analysis of patient samples 
were negative for Dengue and Chikungunya, 
pathogenic re-emerging arboviruses (Lanciotti et al. 
2008), but were positive for Zika by RT-PCR after 
detecting a 364bp amplicon expected only for Zika 
(Zanluca et al. 2015). However, in 2015 the world’s 
attention was drawn to Brazil, when there was an 
increase in the number of microcephaic babies being 
born by pregnant women (Victora 2016). The number 
was initially below 200 prior to 2015 (Brazil Ministry 
of Health 2016). However, this figure increased to 
4783 towards the later part of 2015 and the earlier part 
of 2016 (Brazil Ministry of Health, 2016).  
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Classification 
 
Zika virus belongs to the family Flaviviridae which 
also includes other viruses such as dengue (DENV), 
Yellow Fever and West Nile viruses. All of these are 
of public health importance (Pierson & Diamond 2013, 
Faye et al. 2014). This virus has a single-stranded 
RNA genome with a positive sense polarity (Faye et 
al. 2014) and falls in group four according to the 
Baltimore system of classifying viruses.  
The Zika viral genome is composed of 10,794 
nucleotides which code for 3,419 amino acids (Kuno  
et al. 2007). The Zika virus genome, which acts as 
mRNA upon reaching the cytoplasm, is immediately 
translated into a polyprotein which is cleaved into 3 
structural proteins; capsid (C), precursor membrane 
(prM), envelope (E) and 7 non-structural proteins 
(Kuno  et al. 2007). 
Flavivirus are known to replicate near the 
endoplasmic reticulum of the infected cell. However, 
some studies have reported Zika viral antigens in the 
nucleus of an infected cell, which requires further 
investigation (Buckley et al. 1988). Zika virus was 
classified into African and Asian lineages by 
phylogenetic analysis (Gatherer 2016). The Asian 
lineage originated during the virus’s migration from 
Africa to Southeast Asia, where it was first detected in 
Malaysia. From there, Zika virus spread to the Pacific 
Islands, separately to Yap and French Polynesia, and 
then to New Caledonia, Cook Islands, Easter Island, 
and the Americas (Gatherer 2016). 
 
Transmission 
 
The vector that has been globally identified to transmit 
Zika virus is the Aedes species of mosquito. They are 
able to survive both tropical and temperate climatic 
conditions (Ledermann et al. 2014, Kraemer et al. 
2015, Gaffigan  et al. 2016). Aedes aegypti and Aedes 
albopictus have a wider global coverage as they are 
able to survive both climatic conditions. However, 
some species, namely Aedes luteocephalus in Africa 
and Aedes hensilli in the Pacific Islands, have limited 
global distribution. The Aedes aegypti is the main 
species of mosquito for transmission of Zika virus as 
its feeding habit of biting multiple hosts to complete its 
blood meals tends to spread the virus in the process. 
The mosquito is infected during a blood meal from an 
infected host which could be humans or animals after 
which the virus replicates within the vector and is later 
transmitted to another host which could be man during 
its next blood meal (Ioos et al. 2014). This species of 
mosquito is also known to transmit Dengue virus 
(Thomas et al. 2016). Aedes albopictus has not been 
implicated in most cases of Zika infections. However, 
in 2007, it was implicated in an outbreak of Zika 
infection in Gabon. Also, Aedes albopictus is endemic 
in the U.S.A. and the ability of the virus to survive in 
any Aedes species of mosquito indicates the Aedes 
albopictus vectoral role of Zika virus in the United 
States (Fauci et al. 2016). 
Beside vector transmission, various research 
groups have shown evidence of other modes of 
transmission of the Zika virus. Transplacental 
transmission has been confirmed and is currently a 
global concern as infected babies are born with 
microcephaly (Schuler-Faccini et al. 2016). Sexual 
transmission of Zika virus has also been reported 
(Musso et al. 2015). Thus, some countries, like the 
U.S.A, have recommended couples who have visited 
endemic areas to delay child bearing, and advised 
couples to use condoms to reduce the spread of the 
virus.  In an outbreak in French Polynesia, Zika virus 
was isolated from the semen of a patient diagnosed 
with hematospermia (Musso et al. 2015). In addition, a 
case of sexual transmission of Zika virus was reported 
in France in a woman who acquired Zika sexually 
from her partner who had recently visited Brazil (Elgot 
et al. 2016). CDC also is in the process of 
investigating 14 potential sexually acquired Zika virus 
cases (Duhaime-Ross 2016). 
Zika virus has also been identified as one of the 
possible transfusion transmissible infections in 
addition to others like HIV and hepatitis B (Musso et 
al. 2014). The virus was detected by PCR in 42 (3%) 
of the 1505 blood samples donated from asymptomatic 
donors in French Polynesia (Musso et al. 2014). This 
finding suggested the Zika virus being a transfusion 
transmissible virus, which should be screened for 
before transfusing patients (Musso et al. 2014). 
Another report detected Zika virus serologically in 
blood donors in a Zika endemic area (Aubry et al. 
2015).  
 
Clinical manifestation 
 
Concerning symptoms, Zika infection mimics that of 
Dengue (Ioos et al. 2014). Thus, Zika was previously 
misdiagnosed in patients as Dengue infection (Oehler 
et al. 2014). The period between infection and onset of 
clinical symptoms is approximately 3 to 12 days (Anna 
et al. 2016). However, infection is asymptomatic in 
approximately 80% of cases (Duffy et al. 2009, Ioos et 
al. 2014).  The clinical symptoms manifest as a self-
limited febrile syndrome associated with rash, 
conjunctivitis and arthralgias (Simpson 1964, Musso et 
al. 2016, Petersen et al. 2016). Rash, a prominent 
feature, is maculopapular and pruritic in most cases; it 
begins proximally and spreads to the extremities with 
spontaneous resolution within 1–4 days of onset 
(Simpson, 1964) while fever is typically low grade 
(37.4°C – 38.0°C) (Dupont-Rouzeyrol et al. 2014, 
Musso et al. 2015, Simpson 1964).  
 
Pathogenesis 
 
Currently, two diseases that have been reported to be 
associated with Zika virus infection are microcephaly 
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and Guillain–Barré syndrome (Cao-Lormeau et al. 
2016, Oliveira et al. 2016). Microcephaly is a 
condition that results from the virus attacking the 
neural progenitor cells, disrupting their development 
and thereby affecting the formation of the fetal brain 
which affects the baby’s development (Brasil et al. 
2016, Marrs et al. 2016, Dang et al. 2016, Garcez et al. 
2016, Qian et al. 2016, Tang et al. 2016). Neural 
progenitor cells (NPC) are self-renewing neural stem 
cells in the brain which differentiate into neurons, 
astrocytes, and oligodendrocytes (Delvecchio et al. 
2016). Several research findings have established the 
link between Zika virus and microcephaly such as 
detection of viral RNA in the amniotic fluid of Zika 
infected pregnant women as well as in brain tissues 
from microcephalic babies (Brasil et al. 2016, Calvet 
et al. 2016, Driggers et al. 2016, Mlakar et al. 2016, 
Melo et al. 2016). In vivo experiments where pregnant 
mice were infected with Zika led to neuronal death, 
cell cycle arrest and apoptosis of NPCs leading to 
embryonic microcephaly and growth restriction 
(Cugola et al. 2016, Li et al. 2016, Miner et al. 2016, 
Shao et al. 2016). 
Guillain-Barre syndrome is a rare but serious 
autoimmune disorder in which the immune system 
attacks healthy nerve cells in the peripheral nervous 
system. This leads to weakness, numbness, and 
tingling. It can eventually cause paralysis. Aetologic 
agents that were previous associated with its incidence 
were Campylobacter jejuni, influenza, Epstein-Barr 
virus, Cytomegalovirus and HIV. Recently, clusters of 
the Guillain–Barré syndrome and microcephaly have 
been spatially and temporally related to the current 
outbreak of Zika infection in the Americas (Beatriz et 
al. 2016, World Health Organization 2016). The 
World Health Organization on Feb 1 2016, declared 
Zika associated microcephaly and Guillain-Barre 
syndrome as a Public Health Emergency of 
International Concern (PHEIC), not based on the 
current information of Zika associated cases but on 
what is not known of clusters of microcephaly, 
Guillain-Barré syndrome, and possibly other 
neurological defects reported by country 
representatives from Brazil and French Polynesia 
(Heymann et al. 2016, Oehler et al. 2014, Pan 
American Health Organization 2016). 
 
Laboratory diagnosis 
 
Clinical presentation of patients infected with Zika is 
not reliable for preliminary diagnoses due to its 
similarity with other flaviviruses like Dengue. Thus, 
laboratory diagnosis is used to confirm Zika infection. 
Detection is based on the type of patient sample being 
analyzed. Samples that are currently used for detection 
of Zika infection in patients are blood or serum. 
Viremia is detectable between 3 to 5 days post 
infection. Other samples with Zika diagnostic potential 
are cerebrospinal fluid (CSF), urine, saliva, amniotic 
fluid, semen and fetal brain tissue (Plourde 2016). 
Urine and saliva which are noninvasive samples offer a 
better alternative for diagnosis as compared to blood 
and cerebrospinal fluid. Also, in most cases, collection 
of urine and saliva does not need any technical 
expertise as compared to blood and CSF which is 
collected by trained health professional in a designated 
health facility. Urine samples are currently 
recommended for diagnosis of Zika virus infection as 
viral RNA persists longer in urine as compared to 
blood  (Plourde 2016, Gourinat et al. 2014, Besnard et 
al. 2014). One study reported that Zika virus RNA was 
detected in urine up to 20 days post infection after 
viral RNA was undetectable in the blood (Plourde 
2016). Thus a patient urine sample must also be tested 
to confirm diagnosis when a negative blood test is 
reported for a Zika suspected patient. Detection of 
Zika viral RNA in saliva is best during the acute phase 
of the infection but is not ideal during the late stage. 
Musso et al. (2015) screened 182 Zika suspected 
patient’s saliva and urine samples. Zika viral RNA was 
positive for 35 (19.2%) of their saliva while negative 
in their blood. On the other hand, 16 (8.8%) of the 
patients tested positive for Zika viral RNA in their 
blood but were negative in their saliva. This indicates 
that blood samples should also be screened in cases 
where saliva is used for Zika diagnosis. 
 
Techniques for diagnosis 
 
Serology and molecular diagnoses are currently the 
techniques being used for confirming Zika infection in 
patients. Detection of Zika virus in the blood or serum 
by molecular techniques, namely RT-PCR, is best 
during the acute stage of the infection when the patient 
is viremic (Lanciotti et al. 2008). However, serology 
cannot be used as Zika virus IgM may be undetectable 
during the acute phase of the infection (Hayes 2009). 
Serologic testing has a major limitation. Cross-
reactivity with other flaviviruses (particularly Dengue), 
limits specificity (Beatriz et al. 2016). Therefore, posi-
tive serologic test results should be confirmed with 
molecular testing. The plaque reduction neutralization 
assay, a seroneutralization assay, generally has 
improved specificity over serology, but may still yield 
cross-reactive results in secondary Flavivirus 
infections (Hayes 2009, Anna et al. 2016).   
Currently according to the CDC, symptomatic 
Zika suspected infected patients are diagnosed by 
RNA NAT (nucleic acid testing). Serum samples are 
tested two weeks after the onset of dengue-like 
symptoms. Urine samples are also tested before the 
14th day after the onset of symptoms. A positive result 
is confirmatory of Zika infection. However, a negative 
result does not exclude infection. Additional serum 
IgM testing must be done to rule out infection 
(Diagnostic Tests for Zika Virus, 2017).  
In the case of pregnant women who fall under the 
high risk group, RNA nucleic acid testing must be 
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done on both serum and urine two weeks after any 
visit to a Zika endemic region. In addition, RNA 
testing must be done for those who are IgM positive 
for Zika after exposure. Pregnant women are routinely 
screened for Zika as part of their antenatal care in areas 
where Zika is endemic, especially during the 1st and 
2nd trimester of pregnancy as most of the 
developmental processes of the growing fetus takes 
place at this stage (Diagnostic Tests for Zika Virus 
2017). 
The Trioplex Real-time RT-PCR Assay (Trioplex 
rRT-PCR) is a laboratory test designed to detect Zika 
virus, Dengue virus, and Chikungunya virus RNA 
(Centers for Disease Control and Prevention, 2016). 
This method has not yet received approval for Zika 
diagnosis by the Food and Drug Administration (FDA) 
except on Emergency Use Authorization (EUA) 
according to the CDC. The Trioplex rRT-PCR 
qualitatively detects and differentiates Zika from other 
Flavivirus in human sera, whole blood (EDTA), 
cerebrospinal fluid, urine and amniotic fluid. 
According to the CDC, patient samples analyzed by 
this assay must meet certain criteria; namely clinical 
signs and symptoms associated with Zika virus 
infection, history of residence in or travel to a 
geographic region with active Zika transmission at the 
time of travel, or other epidemiologic criteria for 
which Zika virus testing may be indicated as part of a 
public health investigation. A negative result must be 
combined with clinical observations, patient history, 
and epidemiological information (Centers for Disease 
Control and Prevention, 2016).  
However, this assay can give both false positive 
and false negative results. False positive results can 
arise from contamination from previous positive 
samples. However, inclusion of negative controls helps 
detect any possible contamination of patient samples, 
thereby reducing their incidence. False negative results 
occur as a result of the method of sample collection 
which affects the quality of the sample analyzed,  
degradation of the viral RNA during sample 
transportation, the time of sample collection and 
analysis when viral RNA might no longer be 
detectable in some samples after the onset of 
symptoms (approximately 14 days post-onset of 
symptoms for serum, whole blood, and/or urine),  
failure to follow the authorized assay procedures and 
failure to use authorized extraction kits and platforms 
(Centers for Disease Control and Prevention CDC 
2016, Plourde 2016, Musso et al. 2015). Addition of 
controls helps to assess the quality of samples as well 
as adhering to CDC guidelines on the use of assays 
helps reduce false negative and false positive results.  
Proteomics, a tool that utilizes genetic signatures, 
is currently also being explored by many research 
groups for early diagnosis of diseases, vaccine and 
antiviral production. This molecular based technique 
has led to early identification and quantification of 
functionally active biomarkers at specific time points 
during disease progression. The technique can be used 
to detect the disease process caused by the virus early 
after infection and to prevent the pathology observed 
after infection. Also, the high sensitivity and 
specificity of this technique reduces false positive and 
negative results. Garcez et al. (2016) used combined 
proteomics to analyze human neurospheres derived 
from neural stem cells exposed to Zika virus (ZIKV) 
isolated in Brazil and identified 500 genes and proteins 
altered after viral infection, which contribute to the 
development of microcephaly in infected babies.  
Amongst the proteins detected, 199 were 
downregulated and 259 were upregulated when mock 
and Zika infected neurosphere protein expression 
profiles were compared (Garcez et al. 2016).  
Although biomarkers can help for the early diagnosis 
of a disease, they must be adequately validated over a 
period of time before being used for confirmation of a 
disease process. 
The Zika outbreak in Brazil raised a lot of 
concern globally as there was little information about 
methods for diagnosing Zika as well as vaccine and 
antivirals for prevention. Currently, however, samples 
for detection of Zika infection as well as methods for 
diagnosing infection have been identified, thereby 
improving management of infected patients. In 
addition, two DNA ZIKV vaccine candidates have 
entered phase 1 human safety testing 
(ClinicalTrials.gov numbers, NCT01099852 and 
NCT0284048) (Marston et al. 2016). Thus, getting an 
effective vaccine for immunological protection is 
closer than expected. An effective antiviral is also 
being researched currently at the National Institutes of 
Health (NIH); compounds having antiviral properties 
are being screened to determine their antiviral effect on 
Zika (Awasthi 2016). 
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